A Study of Tofacitinib in Patients With Ulcerative Colitis in Stable Remission
A Study of Tofacitinib in Patients With Ulcerative Colitis in Stable Remission. A Phase 3b/4, Multi-Center, Double-Blind, Randomized, Parallel Group Study of Tofacitinib (CP-690,550) in Subjects With Ulcerative Colitis in Stable Remission.
Category & Conditions: Immune System Diseases and Conditions
Medicine: XELJANZ®(TOFACITINIB)
ClinicalTrials.gov Identifier (NCT): NCT03281304
Protocol ID: A3921288
PrintDownloadOpen Plain Language Summary Result: Click here